Q-omics provides the consensus-scored C17orf99 profile across patient tissues and cancer cell-line models. C17orf99 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C17orf99 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, C17orf99 RNA expression shows 10,022 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, and ESCA as cancer lineages where C17orf99 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf99 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf99 survival associations across molecular data types. C17orf99 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf99 RNA expression–survival associations across cancer types. High C17orf99 expression shows unfavorable associations in KIRP, THCA and COAD, but favorable associations in HNSC, CESC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C17orf99 RNA expression.
This table summarizes C17orf99 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C17orf99. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf99 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, LUSC, LIHC and BLCA. The HNSC box plot shows higher C17orf99 RNA expression in tumor versus normal tissue (log2 FC = +0.847, t-test p < 0.001).
This table shows molecular features associated with C17orf99 in patient tissues and cancer cell lines. In patient samples, C17orf99 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf99 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
